-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Ultragenyx Pharmaceutical, Lowers Price Target to $47

Benzinga·12/30/2025 17:54:50
語音播報
Baird analyst Joel Beatty maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Outperform and lowers the price target from $72 to $47.